Hikal Ltd
Hikal Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Pharmaceutical Business: Expected low-teens revenue growth (12%-14%) in FY '26, recovering from volume deferrals due to US FDA OAI status. The Pharmaceutical segment faced deferment of revenues due to the US FDA OAI status but expects recovery in Q2 and Q3 of FY '26, with no anticipated overall revenue or margin impact for the full year.
From Hikal Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Pharmaceutical Business: Expected low-teens revenue growth (12%-14%) in FY '26, recovering from volume deferrals due to US FDA OAI status. Commercial production and validation of new molecules anticipated by FY '26-FY '28.
- Crop Protection Business: Flattish revenue growth expected in FY '26 amid global overcapacity and pricing pressures, with seasonal volume recovery anticipated in H2 FY '26.
- Animal Health Segment: Steady progress with commercial launches planned from FY '26 onwards; diversification and portfolio expansion expected to drive long-term growth.
- CDMO Segment: Robust and diversified pipeline with commercial revenues expected toward end of FY '26; growth driven by China-plus-one strategy and global innovators.
- Specialty Chemicals: Plant conversion and validation underway, with commercial production expected in 6-9 months, supporting future revenue growth.
- Overall Outlook: Improvement expected in H2 FY '26; Q4 FY '26 anticipated as strongest quarter led by enhanced plant utilization and new product launches.
Profitability & Margins
See what Hikal Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Q1 FY26 CAPEX was Rs. 31 crores focused on debottlenecking, regulatory upgrades, and CDMO capacity augmentation.
- Full-year CAPEX guidance remains Rs. 200 crores, with disciplined allocation towards high ROI projects aligned with long-term growth.
- Ongoing facility and quality control upgrades as part of corrective measures post US FDA OAI status; includes some capital expenses.
- Conversion of part of the specialty chemicals plant into Pharma and Animal Health production; refitting in progress with commercial production expected in 6-9 months.
- Investments continue to enhance pilot-scale capacities and project management for CDMO clients supporting early-stage programs.
- Emphasis on capital allocation towards projects supporting regulatory readiness, operational excellence, and expansion in differentiated chemistries.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- No explicit mention of the current or expected order book value was provided on page 17.
- Customers have deferred shipments due to the OAI status at the Bangalore facility; however, no orders have been canceled.
- Deferred revenue is approximately Rs. 50 crores from Q1, expected to be realized in Q2 and Q3.
- Customers have reaffirmed their commitment to pick up products within Q2 and Q3.
- The company is confident of recovering deferred volumes by end of the second and third quarters of FY '26.
- The CDMO pipeline remains robust and diversified, with multiple projects transitioning from early development to pilot scale; commercial revenues expected towards the end of FY '26.
- Overall, the company sees no loss of orders, only deferments, and maintains a healthy pipeline.
Hikal Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹519 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hikal Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sai Life Sciences Ltd (Q1 FY26)
Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). Key concall takeaways from Sai…
- Cipla Ltd (Q1 FY26)
One Africa business grew 11% YoY, with continued focus on expansion. Key concall takeaways from Cipla's Q1 FY26 earnings call — and how it ranks against sector…
- Anthem Biosciences Ltd (Q1 FY26)
Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. Key concall takeaways from…
- Senores Pharmaceuticals Ltd (Q1 FY26)
. Key concall takeaways from Senores Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Hikal Ltd Q1 FY26 results?
Pharmaceutical Business: Expected low-teens revenue growth (12%-14%) in FY '26, recovering from volume deferrals due to US FDA OAI status. The Pharmaceutical segment faced deferment of revenues due to the US FDA OAI status but expects recovery in Q2 and Q3 of FY '26, with no anticipated overall revenue or margin impact for the full year.
What is Hikal Ltd share price analysis?
Hikal Ltd currently shows a neutral. The stock trades at a P/E of 63.4 with a market cap of ₹2,688 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hikal Ltd planning capital expenditure?
Q1 FY26 CAPEX was Rs.
Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.